Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
HRB H & R Block Inc
GM General Motors Co
NDAQ Nasdaq Inc
DYYXF DB Commodity Double Long ETN
KIQ Kelso Technologies Inc
CBOE Cboe Global Markets Inc
PFE Pfizer Inc
DOW Dow Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Day's Change
-0.0323 (-4.88%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 1,924,874 shares is on pace to be much greater than NBRV's 10-day average volume of 2,903,555 shares.


Wendy's same-restaurant sales turn down 20% in most recent week, company draws down full revolving financing facility

7:36 am ET March 26, 2020 (MarketWatch)

Wendy's Co. (WEN) said for the most recent week ending March 22, the fast-food chain saw same-restaurant sales turn down 20%. For the quarter-to-date, same-restaurant sales are up 2.8% after the breakfast launch drove up sales 15% in its first week. While the dining room is closed, Wendy's continues to operate with drive-thru and digital ordering at most of its restaurants, with drive-thru comprising 90% of the company's business. Wendy's said about 3.5% of all system restaurants are closed, 46 in the U.S. and 189 internationally. Wendy's also announced that it has drawn down its full $120 million revolving financing facility, bringing its cash on hand total to more than $340 million. Share repurchases have been suspended, and the capital plan and general expenditures are under review for cost-saving measures. The company's 2020 and longer-term outlook have been withdrawn. In order to help franchisees, Wendy's is eliminating its incremental marketing spend for its new breakfast menu, deferring royalty payments and taking other measures. Wendy's stock has taken a 15.1% tumble over the last year while the S&P 500 index is down 12.2% for the period.

-Tonya Garcia; 415-439-6400;

(END) Dow Jones Newswires

March 26, 2020 07:36 ET (11:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.